Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Fineline Cube Sep 8, 2026
Company Drug

Aosaikang Pharmaceutical Receives NMPA Review for ASKC200 Liniment from Propella Therapeutics

Fineline Cube Apr 14, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the National Medical Products Administration...

Company R&D

HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency

Fineline Cube Apr 14, 2023

HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the...

Company Deals

Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion

Fineline Cube Apr 14, 2023

PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed...

Company

Huadong Medicine Reports 9.12% YOY Revenue Growth and 13.24% Increase in Net Profits for 2022

Fineline Cube Apr 14, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has released its 2022...

Company

BeiGene Launches LATAM Expansion with New Office in São Paulo, Brazil

Fineline Cube Apr 14, 2023

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced its first...

Company R&D

Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment

Fineline Cube Apr 13, 2023

US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its...

Company Drug

Convalife Pharmaceuticals’ Mefuparib Earns Orphan Drug Designation for Cholangiocarcinoma

Fineline Cube Apr 13, 2023

Shanghai-based Convalife Pharmaceuticals has announced that it has received orphan drug designation (ODD) status from...

Company Deals

VintaBio Secures $64M Funding to Revolutionize Viral Vectors for Cell and Gene Therapy

Fineline Cube Apr 13, 2023

New biotech VintaBio, founded in Philadelphia, Pennsylvania (United States), announces the appointment of CEO David...

Company Deals

Alebund Pharmaceuticals Secures $29M in Pre-Series C Funding and $116M Loan for R&D and Manufacturing

Fineline Cube Apr 13, 2023

Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB...

Company Drug

Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R/R DLBCL

Fineline Cube Apr 13, 2023

Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China’s Overland Pharmaceuticals and Swiss...

Company Drug

Novartis’ Jakavi Secures NMPA Approval for Acute GVHD Treatment in China

Fineline Cube Apr 13, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received a new indication...

Company Drug

Chengdu Hyperway Pharmaceuticals’ HBW-004285 Gets NMPA Tacit Approval for Pain Treatment

Fineline Cube Apr 13, 2023

China-based Chengdu Hyperway Pharmaceuticals has announced receiving tacit clinical trial approval from the National Medical...

Company Medical Device

Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study

Fineline Cube Apr 12, 2023

Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that its Iberis multi-electrode renal...

Company Drug

Grand Pharmaceutical’s APP13007 Achieves Clinical Endpoints in US Trials for Post-Operative Treatment

Fineline Cube Apr 12, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that a Phase II clinical study...

Company Drug

Sirnaomics Commences Phase I Clinical Trial for Factor Xl RNAi Drug STP122G

Fineline Cube Apr 12, 2023

Sirnaomics Ltd (HKG: 2257) has announced the commencement of a single-center, randomized, double-blind, placebo-controlled, sequence...

Company Drug

Shanghai Fosun Pharmaceutical Submits Market Approval Filing for Daxibotulinumtoxin A in China

Fineline Cube Apr 12, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a market approval filing to...

Company Drug

Junshi Biosciences’ Senaparib Meets Primary Endpoint in Phase III Ovarian Cancer Study

Fineline Cube Apr 12, 2023

China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has declared that the Phase III FLAMES study...

Company

Porton Pharma Solutions Expands with Biomacromolecules R&D and Manufacturing Center in Shanghai

Fineline Cube Apr 12, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has initiated the construction of...

Company Deals

Blueray Med Secures Tens of Millions in Series A+ Financing for Advanced Laser Medicine Devices

Fineline Cube Apr 12, 2023

Blueray Med, a leading high-end laser medicine device manufacturer based in Xi’an, has reportedly secured...

Company Deals

Specialised Therapeutics to Commercialize Akeso’s PD-1 Inhibitor Penpulimab in APAC

Fineline Cube Apr 12, 2023

Singapore-based Specialised Therapeutics Asia Pte Ltd (ST) has been appointed to handle the commercialization of...

Posts pagination

1 … 589 590 591 … 717

Recent updates

  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
  • Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Company Deals

Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.